BMO Capital Markets Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price upped by BMO Capital Markets from $725.00 to $850.00 in a report released on Thursday morning,Benzinga reports. BMO Capital Markets currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on the stock. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. HSBC began coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, November 24th. They set a “buy” rating and a $255.00 price target for the company. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 14th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday. Finally, Hsbc Global Res upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $777.36.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $722.80 on Thursday. The stock has a 50 day moving average of $647.61 and a 200 day moving average of $587.69. The company has a market capitalization of $75.97 billion, a price-to-earnings ratio of 17.31, a PEG ratio of 2.07 and a beta of 0.37. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $800.99. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter in the previous year, the firm earned $12.46 earnings per share. The business’s revenue was up .9% on a year-over-year basis. As a group, sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Insider Activity

In other news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. PGGM Investments lifted its stake in shares of Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock valued at $44,308,000 after buying an additional 51,900 shares in the last quarter. Founders Capital Management LLC raised its holdings in Regeneron Pharmaceuticals by 7.0% during the second quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock valued at $4,344,000 after acquiring an additional 538 shares during the period. Sepio Capital LP lifted its position in shares of Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock valued at $2,150,000 after acquiring an additional 842 shares in the last quarter. Generate Investment Management Ltd bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth about $6,300,000. Finally, Bellecapital International Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 32.7% in the second quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock worth $13,389,000 after acquiring an additional 6,283 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.